Potential of transcatheter aortic valve replacement to improve post-procedure renal function

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFAILLACE, Bruno L. R.
dc.contributor.authorRIBEIRO, Henrique B.
dc.contributor.authorCAMPOS, Carlos M.
dc.contributor.authorTRUFFA, Adriano A. M.
dc.contributor.authorBERNARDI, Fernando L.
dc.contributor.authorOLIVEIRA, Marcos D. P.
dc.contributor.authorMARIANI JR., Jose
dc.contributor.authorMARCHINI, Julio F.
dc.contributor.authorTARASOUTCHI, Flavio
dc.contributor.authorLEMOS, Pedro A.
dc.date.accessioned2017-12-12T13:21:44Z
dc.date.available2017-12-12T13:21:44Z
dc.date.issued2017
dc.description.abstractBackground: Baseline comorbidities including renal dysfunction are frequently found in patients treated with transcatheter aortic valve replacement (TAVR) and may increase the risks of acute kidney injury (AKI), although some of them may actually improve renal function. We aimed to evaluate the potential of TAVR to acutely improve post-procedure renal function. Methods: This is a prospective single-center registry of consecutive patients with severe symptomatic aortic stenosis treated by transfemoral TAVR. Creatinine levels were determined at baseline and daily until hospital discharge. AKI was defined according to VARC-2 criteria. Patients who had improvement of creatinine levels >25% were classified as having TAVR induced renal function improvement (TIRFI). Results: A total of 69 patients undergoing TAVR were included, with a mean age of 83.0 +/- 7.4 years, being 24.6% diabetics, with a median STS score of 9.2 (5.1-21.6). Using the VARC-2 criteria, the majority of patients (64.6%) did not have renal impairment, while AKI was detected in 35.4% of the patients. Importantly, in those with prior severe renal dysfunction (clearance <30 mL/min/1.73 m(2)) or diabetes, AKI reached up to 50% and 56.3% of the patients, respectively. Conversely, acute kidney recovery (TIRFI) occurred in 12 patients (18.5%) being >50% in 1 patient (1.5%), and at hospital discharge the majority of the patients (88.6%) left the hospital in their original or better renal function categories. Conclusion: Despite multiple comorbidities in a selected TAVR-population and the use of contrast media, TAVR did not impair renal function in a majority of patients, with a significant proportion of them rather having acute renal function improvement.
dc.description.indexMEDLINE
dc.identifier.citationCARDIOVASCULAR REVASCULARIZATION MEDICINE, v.18, n.7, p.507-511, 2017
dc.identifier.doi10.1016/j.carrev.2017.03.031
dc.identifier.eissn1878-0938
dc.identifier.issn1553-8389
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/24437
dc.language.isoeng
dc.publisherELSEVIER INC
dc.relation.ispartofCardiovascular Revascularization Medicine
dc.rightsrestrictedAccess
dc.rights.holderCopyright ELSEVIER INC
dc.subjectTranscatheter aortic valve implantation
dc.subjectRenal improvement
dc.subjectAcute kidney injury
dc.subjectRenal failure
dc.subject.otheracute kidney injury
dc.subject.othercontrast-induced nephropathy
dc.subject.otherimplantation
dc.subject.otherrisk
dc.subject.otheroutcomes
dc.subject.otherdefinition
dc.subject.otherstenosis
dc.subject.otherdisease
dc.subject.wosCardiac & Cardiovascular Systems
dc.titlePotential of transcatheter aortic valve replacement to improve post-procedure renal function
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.citation.scopus10
hcfmusp.contributor.author-fmusphcBRUNO LUIGI ROCHA FAILLACE
hcfmusp.contributor.author-fmusphcHENRIQUE BARBOSA RIBEIRO
hcfmusp.contributor.author-fmusphcCARLOS AUGUSTO HOMEM DE MAGALHAES CAMPOS
hcfmusp.contributor.author-fmusphcADRIANO AUGUSTO MEIRELLES TRUFFA
hcfmusp.contributor.author-fmusphcFERNANDO LUIZ DE MELO BERNARDI
hcfmusp.contributor.author-fmusphcMARCOS DANILLO PEIXOTO OLIVEIRA
hcfmusp.contributor.author-fmusphcJOSE MARIANI JUNIOR
hcfmusp.contributor.author-fmusphcJULIO FLAVIO MEIRELLES MARCHINI
hcfmusp.contributor.author-fmusphcFLAVIO TARASOUTCHI
hcfmusp.contributor.author-fmusphcPEDRO ALVES LEMOS NETO
hcfmusp.description.beginpage507
hcfmusp.description.endpage511
hcfmusp.description.issue7
hcfmusp.description.volume18
hcfmusp.origemWOS
hcfmusp.origem.pubmed29054156
hcfmusp.origem.scopus2-s2.0-85031765873
hcfmusp.origem.wosWOS:000414499500010
hcfmusp.publisher.citySAN DIEGO
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceAllende R, 2014, EUR HEART J, V35, P2685, DOI 10.1093/eurheartj/ehu175
hcfmusp.relation.referenceAregger F, 2009, NEPHROL DIAL TRANSPL, V24, P2175, DOI 10.1093/ndt/gfp036
hcfmusp.relation.referenceBagur R, 2010, EUR HEART J, V31, P865, DOI 10.1093/eurheartj/ehp552
hcfmusp.relation.referenceBarbanti M, 2015, JACC-CARDIOVASC INTE, V8, P1595, DOI 10.1016/j.jcin.2015.07.012
hcfmusp.relation.referenceFinn WF, 2006, NEPHROL DIAL TRANSPL, V21, pi2, DOI 10.1093/NDT/GFL213
hcfmusp.relation.referenceGruberg L, 2000, J AM COLL CARDIOL, V36, P1542, DOI 10.1016/S0735-1097(00)00917-7
hcfmusp.relation.referenceHahn RT, 2013, J AM COLL CARDIOL, V61, P2514, DOI 10.1016/j.jacc.2013.02.087
hcfmusp.relation.referenceKappetein AP, 2012, J AM COLL CARDIOL, V60, P1438, DOI 10.1016/j.jacc.2012.09.001
hcfmusp.relation.referenceKeles T, 2013, J GERIATR CARDIOL, V10, P317, DOI 10.3969/j.issn.1671-5411.2013.04.010
hcfmusp.relation.referenceKhatri PJ, 2013, ANN INTERN MED, V158, P35, DOI 10.7326/0003-4819-158-1-201301010-00007
hcfmusp.relation.referenceLe Ven F, 2013, J AM COLL CARDIOL, V62, P782, DOI 10.1016/j.jacc.2013.05.044
hcfmusp.relation.referenceLeon MB, 2016, N ENGL J MED
hcfmusp.relation.referenceLevey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x
hcfmusp.relation.referenceMangano CM, 1998, ANN INTERN MED, V128, P194
hcfmusp.relation.referenceMehran R, 2006, KIDNEY INT, V69, pS11, DOI 10.1038/sj.ki.5000368
hcfmusp.relation.referenceMehran R, 2004, J AM COLL CARDIOL, V44, P1393, DOI 10.1016/j.jacc.2004.06.068
hcfmusp.relation.referenceMehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713
hcfmusp.relation.referenceNuis RJ, 2012, CIRC-CARDIOVASC INTE, V5, P680, DOI 10.1161/CIRCINTERVENTIONS.112.971291
hcfmusp.relation.referenceRibeiro HB, 2014, PROG CARDIOVASC DIS, V56, P583, DOI 10.1016/j.pcad.2014.02.001
hcfmusp.relation.referenceRodes-Cabau J, 2012, NAT REV CARDIOL, V9, P15, DOI 10.1038/nrcardio.2011.164
hcfmusp.relation.referenceTepel M, 2006, CIRCULATION, V113, P1799, DOI 10.1161/CIRCULATIONAHA.105.595090
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication32c4d631-7b33-4610-8f25-fca398e767d6
relation.isAuthorOfPublication2fee1ac1-2e9a-43c1-bef1-d8ac78e3b1b1
relation.isAuthorOfPublicationd5b3a1f1-e31e-406b-bb17-ab5dfa6f93da
relation.isAuthorOfPublication867f3cb0-8748-430c-b077-35895e5fddf2
relation.isAuthorOfPublication389e3674-2037-4124-9f9a-833d132f62ba
relation.isAuthorOfPublication81c672bf-a622-44ad-9711-47a5563e00b7
relation.isAuthorOfPublication0d23295e-d092-48c8-9291-0b008ef5fa33
relation.isAuthorOfPublication707a90ae-9138-40b4-a33c-9ff88d5348f7
relation.isAuthorOfPublication68dfcbfe-558c-42dc-9403-9e79e74b5775
relation.isAuthorOfPublicatione5f6197a-e11d-4b47-af40-0542e85351f2
relation.isAuthorOfPublication.latestForDiscovery32c4d631-7b33-4610-8f25-fca398e767d6
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_FAILLACE_Potential_of_transcatheter_aortic_valve_replacement_to_improve_2017.PDF
Tamanho:
46.43 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/11
Artigos e Materiais de Revistas Científicas - LIM/13
Artigos e Materiais de Revistas Científicas - ODS/03